November 4, 2020

Quarterly Financial Summary
(For the first six months of the fiscal year ending March 31, 2021)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report: November 9, 2020
Scheduled date to commence dividend payments: December 1, 2020
Preparation of supplementary documents to the quarterly financial results: Yes
Holding of quarterly financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2020 through September 30, 2020)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2020	26,809	(11.6)	1,388	(20.2)	1,097	(32.6)	1,218	(1.0)
September 30, 2019	30,317	(0.5)	1,738	(16.0)	1,628	(15.0)	1,230	(46.0)

Note: Comprehensive income: For the six months ended September 30, 2020: 1,809 million yen [–%]
For the six months ended September 30, 2019: (0) million yen [–%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2020	26.36	–
September 30, 2019	26.16	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
September 30, 2020	106,167	53,388	50.1	1,153.59
March 31, 2020	104,155	52,678	50.4	1,134.30

Reference: Equity: As of September 30, 2020: 53,225 million yen As of March 31, 2020: 52,510 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2020	–	17.00	–	17.00	34.00
Year ending March 31, 2021	–	17.00			
Year ending March 31, 2021 (Forecast)			–	17.00	34.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2021 (April 1, 2020 through March 31, 2021)

(Percentage figures indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	61,000	0.9	4,300	5.0	3,900	0.5	3,300	12.8	71.47

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes of subsidiaries during the six months ended September 30, 2020 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the period (including treasury shares):
As of September 30, 2020: 53,119,190 shares As of March 31, 2020: 53,119,190 shares
2) Number of treasury shares as of the end of the period:
As of September 30, 2020: 6,980,224 shares As of March 31, 2020: 6,825,944 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2020: 46,206,490 shares
For the six months ended September 30, 2019: 47,024,857 shares

* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.